5 Key Takeaways

• 1

  Marjan Farid has been appointed chair of Aurion Biotech's medical advisory board, focusing on vision restoration therapies.

• 2

  Farid is a leading surgeon and clinical professor at the Gavin Herbert Eye Institute, UCI, specializing in cornea and cataract surgery.

• 3

  Aurion is developing AURN001, an investigational cell therapy for corneal endothelial disease, currently in Phase 3 clinical trials.

• 4

  In 2024, Aurion launched Vyznova, the first commercially available cell therapy for corneal endothelial disease.

• 5

  Farid's expertise is expected to enhance Aurion's strategic direction and development of regenerative therapies for corneal disease.